Literature DB >> 19297216

The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherothrombosis.

E Tournoij1, R J G Peters, M Langenberg, K J K Kanhai, F L Moll.   

Abstract

Daily low-dose acetylsalicylacid (ASA) is prescribed to patients with atherothrombosis frequently to prevent vascular complications. In reports on complications and side effects of low-dose ASA use in the literature there is a range of definitions. We explored the incidence, characteristics and consequences of symptoms suggestive of ASA intolerance in patients on low-dose ASA. General practitioners and specialists in 105 centres were asked to review their patient files for the last 10 consecutive patients who were prescribed ASA. Participating patients completed a questionnaire about their current ASA use (doctors completed the questionnaire together with the patients), use of co-medication and symptoms suggestive of ASA intolerance. A total of 947 patients were included in this study. Sixty patients (6.6%) had ceased ASA treatment, predominantly because of the occurrence of side effects suspected to be caused by ASA use. A quarter of the patients concomitantly used an anti-acid agent. Of the 947 patients, 271 (30.6%) indicated symptoms during ASA intake. The most common symptoms were related to the gastrointestinal tract (25.1%). In patients prescribed a low-dose of ASA monotherapy, side effects suggestive of intolerance are common. More awareness should be created to detect and treat these symptoms, because the occurrence of side effects is the most important reason for patients to discontinue ASA treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19297216     DOI: 10.1016/j.ejvs.2009.01.009

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  5 in total

1.  Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?

Authors:  Ludger Klimek; Ralph Dollner; Oliver Pfaar; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2014-06       Impact factor: 4.806

2.  [ASA-intolerance syndrome and persistent rhinosinusitis : Differential diagnosis and treatment].

Authors:  H Kirsche; L Klimek
Journal:  HNO       Date:  2015-05       Impact factor: 1.284

3.  Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic Acid: a quantitative study in patients with cardiovascular risk.

Authors:  Christina Moberg; Jørgen Naesdal; Lars-Erik Svedberg; Delphine Duchateau; Nicola Harte
Journal:  Patient       Date:  2011       Impact factor: 3.883

4.  Gastrointestinal comorbidities associated with atrial fibrillation.

Authors:  François Laliberté; Yuliya Moore; Katherine Dea; Joyce C LaMori; Samir H Mody; JaCinda L Jones; Michele D Arledge; C V Damaraju; Jeff R Schein; Patrick Lefebvre
Journal:  Springerplus       Date:  2014-10-15

5.  Cilostazol combined with P2Y12 receptor inhibitors: A substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation.

Authors:  Yikai Zhao; Peng Zhou; Wen Gao; Haoxuan Zhong; Yufei Chen; Wei Chen; Maieryemu Waresi; Kun Xie; Haiming Shi; Hui Gong; Guibin He; Zhaohui Qiu; Xinping Luo; Jian Li
Journal:  Clin Cardiol       Date:  2022-02-04       Impact factor: 2.882

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.